These findings collectively demonstrate that LHFPL6 knockdown in CAFs remodels the tumor-permissive niche into a growth-restrictive microenvironment, establishing LHFPL6 as a CAF-specific prognostic biomarker and potential therapeutic target in CRC. Here, LHFPL6 is linked to neoplasm.